Alkermes, Inc. (ALKS) Reports In-Line Q4 Loss of 14c; Guides FY12
Tweet
Share
E-mailGet Alerts ALKS Hot Sheet
Price: $50.19 -0.18%
Financial Fact:
Research and development: 23.71M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Research and development: 23.71M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
Alkermes, Inc. (NASDAQ: ALKS) reported Q4 EPS of ($0.14), in-line with the analyst estimate of ($0.14). Revenue for the quarter came in at $42.28 million versus the consensus estimate of $46.32 million.
Sees FY12 loss of 38-47c, vs. the consensus of 30c loss. See sales of $205-$229 million, vs. the consensus of $213.7 million.
Sees FY12 loss of 38-47c, vs. the consensus of 30c loss. See sales of $205-$229 million, vs. the consensus of $213.7 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ondas Holdings Inc. (ONDS) Misses Q2 EPS by 9c
- Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
- Forum Markets, Incorporated (FRMM) Tops Q2 EPS by 29c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
